BREAKING
Home » Posts Tagged "Bavarian Nordic"

Smallpox vaccine to be supplied in response to new cases of monkeypox in the UK

By

By NewsDesk  @infectiousdiseasenews Bavarian Nordic A/S  announced Friday that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency...

Canada orders more IMVAMUNE smallpox vaccine

By

Bavarian Nordic A/S  announced today that the Public Health Agency of Canada (PHAC) has ordered IMVAMUNE® smallpox vaccine to the national stockpile at a total value of USD 31.2 million. Deliveries...

IMVAMUNE smallpox vaccine approved for monkeypox and related orthopoxvirus in Canada

By

Bavarian Nordic A/S announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox...

Smallpox vaccine: Bavarian Nordic announces topline results from study on freeze-dried formulation

By

Bavarian Nordic A/S  announced  topline results from the pivotal Phase 3 study of the freeze-dried formulation of its MVA-BN® smallpox vaccine. The Phase 3 lot-consistency study was agreed with the...

Rabies vaccine: Bavarian Nordic announces the launch of distribution and marketing of RabAvert® in the U.S.

By

Bavarian Nordic A/S  announced this week the initiation of full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur®/RabAvert® (Rabies...

Equine encephalitis vaccine: Bavarian Nordic announces topline results from the the first-in-human trial

By

Bavarian Nordic A/S announced today topline results from the the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against three equine encephalitis viruses (western, eastern and...

Equine Encephalitis Virus Vaccine: Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial

By

Bavarian Nordic A/S announced today the initiation of the first-in-human trial of MVA-BN® WEV, a prophylactic vaccine candidate against the equine encephalitis virus – a rare, but potentially deadly...

Smallpox and Monkeypox vaccine, JYNNEOS™, receives FDA approval

By

Bavarian Nordic A/S today announced that the U.S. Food and Drug Administration (FDA) has approved JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) (MVA-BN®, liquid-frozen) for prevention...

Smallpox vaccine enters Phase 3 Trial

By

Bavarian Nordic A/S announced today the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects. The randomized,...

Monkeypox: Smallpox vaccines delivered to UK for healthcare workers

By

After the confirmation on Friday 7thSeptember 2018 of the first case of human monkeypox in England, Public Health England (PHE), as part of their response, engaged Bavarian Nordic to assist in the supply...